Bicara Therapeutics Inc. Common Stock

NASDAQ:BCAX

Biotechnology

Healthcare
$9.12 +0.00%

+$0.00 today

Market cap
$605.45M
Beta
-0.53
P/E (TTM)
-8.8
EPS (TTM)
-$2.59
52W Low $8.48High $24.25

Volume 0.84M

Average 0.54M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$106.83M

FY 2025 · Annual

Investing Cash Flow

-$318.45M

FY 2025 · Annual

Financing Cash Flow

$32.26M

FY 2025 · Annual

-90.3% YoY

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(37.85M)(51.99M)(68M)(137.95M)
Depreciation & Amortization10K19K56K406K
Deferred Income Tax0000
Stock-Based Compensation810K1.9M7.4M15.01M
Change in Working Capital4.95M(9.62M)(14.13M)14.81M
Accounts Receivables0000
Inventory0000
Accounts Payables002.64M0
Other Working Capital4.95M(9.62M)(16.77M)14.81M
Other Non-Cash Items810K14.06M(77K)895K
Operating Cash Flow(32.08M)(45.63M)(74.75M)(106.83M)
Capital Expenditures(192K)(586K)(71K)(280K)
Acquisitions (Net)0000
Purchases of Investments000(318.17M)
Sales of Investments0000
Other Investing Activities0062K0
Investing Cash Flow(192K)(586K)(9K)(318.45M)
Debt Repayment0000
Common Stock Issued00332.43M32.26M
Common Stock Repurchased0000
Dividends Paid0000
Other Financing Activities160K149K1.6M0
Financing Cash Flow31.7M272.5M334.03M32.26M
Effect of Forex Changes0000
Net Change in Cash(573K)226.28M259.27M(393.03M)
Free Cash Flow(32.27M)(46.21M)(74.82M)(107.11M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$137.9M
+ D&A$406.0K
+ Stock-Based Comp$15.0M
+ Deferred Tax$0
+ Working Capital$14.8M
+ Other Non-Cash$895.0K
= Operating Cash Flow-$106.8M
- Capex-$280.0K
= Free Cash Flow-$107.1M

Analysis

FY2025 free cash flow is -$107.1M. FCF conversion is 77.6% of net income. Operating cash flow was -$106.8M, with capex of -$280.0K. The largest bridge item is Stock-Based Comp at $15.0M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
S-8S-8 filingNov 10, 2026
10-QQuarterly reportNov 9, 2026
8-KCurrent reportNov 9, 2026
SC 13G/ASC 13G/A filingOct 7, 2026
4Statement of changes in beneficial ownershipSep 10, 2026

Does BCAX generate free cash flow?

Bicara Therapeutics Inc. Common Stock (BCAX) generated -$107.11M of free cash flow in fiscal 2025.

How much operating cash flow does BCAX produce?

Operating cash flow was -$106.83M, before capital expenditures of $280,000.00.